OncoMatch/Clinical Trials/NCT07750886
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
Is NCT07750886 recruiting? Yes, currently enrolling (Sep 2026).
The SCORE-NHL study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with aggressive Stage I to IV non-Hodgkin Lymphoma (NHL). Study participants will undergo research blood collections of up to 60 mL as well as residual tissue collection, collected as part of a standard of care procedure, for use in research. Collected samples and data will be analyzed to evaluate biomarkers associated with development and validation of cancer monitoring and detection assays ("Natera cancer monitoring and detection test(s)").
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Disease stage
Required: Stage I, II, III, IV
Grade: grade 3b
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: stem cell transplant
History of an allogeneic stem cell transplant or other organ transplant.
Cannot have received: organ transplant
History of an allogeneic stem cell transplant or other organ transplant.
Cannot have received: systemic anticancer therapy
Exception: participants who have undergone surgical removal of skin squamous cell or basal cell cancers
Prior history and treatment for any cancer within the past year or another active cancer, with the exception of participants who have undergone surgical removal of skin squamous cell or basal cell cancers.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Natera, Inc. · Austin, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07750886 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage I or II or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify